LynxBio is developing a platform technology to rapidly identify effective treatment options for cancer patients by characterizing patient-individual cancer behavior & disease evolution, with an initial focus on blood cancers.
Creates an ex vivo model of a patient's cancer and microenvironment using standard of care biopsy
Cellular behavior and response readout able to be integrated with complementary technologies
Seamless integration into clinical workflow with actionable readouts 3 days after biopsy
Identification of all patients as either clinically responsive or non-responsive in first clinical study to a common blood cancer drug